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22 Oral Presentationsthan 18 years of age. All patients had acute leukemia and were trans-
planted in 2000–2006. Median follow-up of surviving patients was 2
years in both treatment groups. There were no significant differences
in patient and disease characteristics, transplant conditioning
regimen, GVHD prophylaxis and donor-recipient HLA disparity
by graft type. Though the early probability of neutrophil recovery
($500/ul) was faster after transplantation of PBPC (31% vs. 10%
at day-14, p\0.001) the probability of recovery by day-28 was similar
after PBPC and BM transplants (94% and 91%, p5 0.391). Platelet
recovery ($20,000/ul) was better after PBPC transplants (86% vs.
76% at day-60, p 5 0.022). Risks of grade 2–4 (hazard ratio [HR]
1.24, p 5 0.147) and grade 3–4 (HR 1.07, p 5 0.785) acute
GVHD were similar after PBPC and BM transplants. The risk of de-
veloping chronic GVHD was significantly greater after PBPC trans-
plants compared to BM transplants (HR 2.36, p\0.001). After
adjusting for disease status, donor-recipient HLA disparity and
age, TRM, relapse, leukemia-free survival and overall survival were
similar after PBPC and BM transplants. In parentheses is shown
the day-100 probability of grade 2–4 acute GVHD (53%/49%) the
3-year probabilities of chronic GVHD (58%/33%), TRM (20%/
24%), relapse (34%/28%), LFS (46%/48%) and overall survival
(49%/49%) for the PBPC/BM groups, respectively. These results
differ from transplantation of PBPC from HLA-matched siblings
To conclude, in patients \18 years of age with acute leukemia,
unrelated PBPC transplant compared to BM resulted in faster recov-
ery of neutrophils and platelets and an increased risk of chronic
GVHD. Acute GVHD, TRM, relapse, survival and LFS were
similar using PBPC or BM.LYMPHOMA/MULTIPLE MYELOMA
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EBV-associated Hodgkin’s Lymphoma (HL) and some non-
Hodgkins lymphoma (NHL) have type II viral latency expressing
the subdominant EBV antigens EBNA1, LMP1 and LMP2. These
antigens may serve as targets for immunotherapy approaches after
stem cell transplant. We hypothesized that CTL enriched for effec-
tor cells specifically targeting LMP antigens would have efficacy in
HL and NHL patients. LMP-CTL were generated using dendritic
cells for initial stimulations then EBV-transformed lymphoblastoid
cell lines (LCL) both of which had been genetically modified to over-
express either LMP2 alone or inactive LMP1 (DLMP1) and LMP2
by transduction with an Ad5f35LMP2 (n 5 16) or Ad5f35DLMP1-
I-LMP2 (n5 14) vector respectively. All LMP-CTL lines were poly-
clonal comprising CD41 (mean 17618%; range 1–92) and CD81
(mean 74 6 25%; range 1–99) T-cells. Flow cytometric analysis of
memory markers revealed mixed populations of CD45RA-
CD62L- T-cells (45615%; range 31–63) and CD45RA- CD62L1
T-cells (3465%; range 28–41). The CTL lines had specificity for
CD41 and CD81 restricted LMP2 epitopes alone (n 5 19; mean
1; range 0–7) or both LMP1 and LMP2 epitopes (n 5 13; mean 2;
range 0–6) per CTL line, as determined using overlapping LMP1
and LMP2 peptide pools in ELISPOT assays. 24 patients with
EBV1 HL and NHL have been treated on dose escalation studies.
16 with LMP2 CTLs and 8 with LMP1/2 CTLs. No immediate
toxicity was observed. After CTL infusion, increased numbers of
LMP-specific T cells were detected in the blood of 15/22 evaluable
patients, (range 2 to 70 fold) persisting for up to 3 months. Addition-
ally, two patients had lymph node biopsies 3–6 months post CTL,
which showed selective accumulation of LMP2-multimer positive
cells in lymph nodes. 12/13 high-risk and/or multiply relapsed pa-
tients who received LMP-CTL as adjuvant treatment after SCT or
chemotherapy remained in remission for a median of 2yrs (range
. 3mths to 5years) after CTL. 11 patients had detectable disease
at the time of CTL, 2 of these had progressive disease by 8 wks
and 9 had clinical responses. The median duration of the clinical
responses is 1 yr with one stable disease (.12months), one partialresponse (36 months), and 7 complete responses (range 9 months
to .4.5 years). In conclusion, immunotherapy with CTL targeting
LMP antigens is well tolerated in patients with EBV1 lymphoma
and infused LMP-CTL can accumulate at tumor sites and induce
complete and sustained clinical responses.53
HLA-IDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION (AL-
LOSCT) FOR PATIENTS WITH PRIMARY CUTANEOUS T-CELL LYMPHOMA
(CTCL): A RETROSPECTIVE ANALYSIS OF THE LYMPHOMA WORKING
PARTY OF THE EUROPEAN BLOOD AND MARROW TRANSPLANTATION
GROUP (EBMT-LWP)
Duarte, R.F.1, Canals, C.2, Onida, F.3, Olavarria, E.4, Arcese, W.5,
Ferrant, A.6, Narni, F.7, Lambertenghi, G.3, Bacigalupo, A.8,
Bunjes, D.9, Rowe, J.M.10, Schmitz, N.11, Sureda, A.2 1Catalan Institute
of Oncology - Duran i Reynals, Barcelona, Spain; 2Hospital Santa Creu i
Sant Pau, Barcelona, Spain; 3OspedaleMaggiore di Milano, Italy; 4Ham-
mersmith Hospital, London, United Kingdom; 5Universita Tor Vergata di
Roma, Italy; 6Cliniques Universitaires St. Luc, Brussels, Belgium;
7Policlinico di Modena, Italy; 8Ospedale San Martino, Genova, Italy;
9University of Ulm, Germany; 10RambamMedical Center, Haifa, Israel;
11Asklepios Klinik St Georg, Hamburg, Germany
Patients with advanced stage Mycosis Fungoides (MF), Sezary syn-
drome (SS) and other less common subtypes of primary CTCL have
a dismal prognosis with conventional therapy. A potential role for
alloSCT in these patients has been suggested by a small number of
case-reports and small series. We have now conducted a retrospective
registry analysis of 64 recipients of an alloSCT from HLA-Identical
donors (52 related, 12 unrelated) for advanced CTCL reported to
EBMT between 1997 and 2006: 23 MF, 21 SS, 16 primary cutaneous
anaplastic large cell lymphoma and 4 subcutaneous panniculitis-like
T-cell lymphoma; 38 male/26 female; median age 46 (5–65); median
follow up in survivors, 28 months). AlloSCT was performed at a me-
dian of 22 (3–313) months from initial diagnosis, following a median
of 3 (1–8) prior lines of therapy, 54 PB and 10 BM as stem cell source,
and using a reduced-intensity conditioning (RIC) in 41 (64%) cases.
Only 23% of patients were in CR and 26% in PR at the time of al-
loSCT. The rest were primary refractory (RE, 25%) or in progression
(PG, 26%). Non-relapse mortality was 24% at 3 years, and appeared
poorer in patients receiving myeloablative conditioning (MAC) than
in those receiving RIC alloSCT (35% vs 16%; p5 0.06). Acute graft
versus host disease (GVHD) occurred in 37% of patients at risk, and
chronic GVHD in 69% of patients alive at day1100. The cumulative
incidence of disease relapse (36% at 3 years) was significantly higher
in patients with advanced disease status at alloSCT (RE/PG 46% vs
CR/PR 21%; p 5 0.01), but similar between related and unrelated
donors (p5 0.39) and between MAC and RIC (p5 0.58). First pro-
gression free survival (PFS) at 3 years was 41%, with a significant ad-
vantage for patients in CR/PR at alloSCT (58% vs 26%; p\0.01), but
not for type of conditioning (MAC 45% vs RIC 44%; p 5 0.44) or
donor type (related 46% vs unrelated 33%; p5 0.17). Out of 22 pa-
tients who relapsed, 10 remain alive and 4 of these are in CR at last
follow up, indicating that a proportion of patients can achieve a better
control of their CTCL following relapse after alloSCT. Overall sur-
vival for the whole series was 55% at 3 years, with a trend towards an
improved OS for patients with disease in CR/PR at transplant (65%
vs 46%; p 5 0.12). Overall, this outcome appears superior to the
expected median OS for these patients with conventional therapy,
and reinforces, in the largest series to date, the important role of
alloSCT in advanced stage CTCL.54
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Autologous hematopoietic cell transplantation (auto HCT) is ef-
fective therapy for patients with advanced Hodgkin (HL) and non-
